Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis

There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial agents for the treatment of many conditions, including cystic fibrosis (CF). The challenging conditions of the CF patient lung require robust AMPs that are active in an environment of high proteolytic a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Forde, Éanna (VerfasserIn) , Schütte, André (VerfasserIn) , Reeves, Emer (VerfasserIn) , Greene, Catherine (VerfasserIn) , Humphreys, Hilary (VerfasserIn) , Mall, Marcus A. (VerfasserIn) , Fitzgerald-Hughes, Deirdre (VerfasserIn) , Devocelle, Marc (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 22 February 2016
In: Antimicrobial agents and chemotherapy
Year: 2016, Jahrgang: 60, Heft: 5, Pages: 2813-2821
ISSN:1098-6596
DOI:10.1128/AAC.00157-16
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1128/AAC.00157-16
Verlag, lizenzpflichtig, Volltext: https://aac.asm.org/content/60/5/2813
Volltext
Verfasserangaben:Éanna Forde, André Schütte, Emer Reeves, Catherine Greene, Hilary Humphreys, Marcus Mall, Deirdre Fitzgerald-Hughes, Marc Devocelle

MARC

LEADER 00000caa a2200000 c 4500
001 1698605188
003 DE-627
005 20220818092636.0
007 cr uuu---uuuuu
008 200520s2016 xx |||||o 00| ||eng c
024 7 |a 10.1128/AAC.00157-16  |2 doi 
035 |a (DE-627)1698605188 
035 |a (DE-599)KXP1698605188 
035 |a (OCoLC)1341325969 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Forde, Éanna  |e VerfasserIn  |0 (DE-588)1208739867  |0 (DE-627)1695562542  |4 aut 
245 1 0 |a Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis  |c Éanna Forde, André Schütte, Emer Reeves, Catherine Greene, Hilary Humphreys, Marcus Mall, Deirdre Fitzgerald-Hughes, Marc Devocelle 
264 1 |c 22 February 2016 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 20.05.2020 
520 |a There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial agents for the treatment of many conditions, including cystic fibrosis (CF). The challenging conditions of the CF patient lung require robust AMPs that are active in an environment of high proteolytic activity but that also have low cytotoxicity and immunogenicity. Previously, we developed prodrugs of AMPs that limited the cytotoxic effects of AMP treatment by rendering the antimicrobial activity dependent on the host enzyme neutrophil elastase (NE). However, cytotoxicity remained an issue. Here, we describe the further optimization of the AMP prodrug (pro-AMP) model for CF to produce pro-WMR, a peptide with greatly reduced cytotoxicity (50% inhibitory concentration against CFBE41o- cells, >300 μM) compared to that of the previous group of pro-AMPs. The bactericidal activity of pro-WMR was increased in NE-rich bronchoalveolar lavage (BAL) fluid from CF patients (range, 8.4% ± 6.9% alone to 91.5% ± 5.8% with BAL fluid; P = 0.0004), an activity differential greater than that of previous pro-AMPs. In a murine model of lung delivery, the pro-AMP modification reduced host toxicity, with pro-WMR being less toxic than the active peptide. Previously, host toxicity issues have hampered the clinical application of AMPs. However, the development of application-specific AMPs with modifications that minimize toxicity similar to those described here can significantly advance their potential use in patients. The combination of this prodrug strategy with a highly active AMP has the potential to produce new therapeutics for the challenging conditions of the CF patient lung. 
700 1 |a Schütte, André  |d 1980-  |e VerfasserIn  |0 (DE-588)140311718  |0 (DE-627)617693897  |0 (DE-576)31637220X  |4 aut 
700 1 |a Reeves, Emer  |e VerfasserIn  |4 aut 
700 1 |a Greene, Catherine  |e VerfasserIn  |4 aut 
700 1 |a Humphreys, Hilary  |e VerfasserIn  |4 aut 
700 1 |a Mall, Marcus A.  |d 1975-  |e VerfasserIn  |0 (DE-588)115507795  |0 (DE-627)691370532  |0 (DE-576)28992152X  |4 aut 
700 1 |a Fitzgerald-Hughes, Deirdre  |e VerfasserIn  |4 aut 
700 1 |a Devocelle, Marc  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Antimicrobial agents and chemotherapy  |d Washington, DC : Soc., 1972  |g 60(2016), 5, Seite 2813-2821  |h Online-Ressource  |w (DE-627)306316919  |w (DE-600)1496156-8  |w (DE-576)09718859X  |x 1098-6596  |7 nnas  |a Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis 
773 1 8 |g volume:60  |g year:2016  |g number:5  |g pages:2813-2821  |g extent:9  |a Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis 
856 4 0 |u https://doi.org/10.1128/AAC.00157-16  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://aac.asm.org/content/60/5/2813  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200520 
993 |a Article 
994 |a 2016 
998 |g 115507795  |a Mall, Marcus A.  |m 115507795:Mall, Marcus A.  |d 910000  |d 910500  |e 910000PM115507795  |e 910500PM115507795  |k 0/910000/  |k 1/910000/910500/  |p 6 
998 |g 140311718  |a Schütte, André  |m 140311718:Schütte, André  |d 910000  |d 910500  |e 910000PS140311718  |e 910500PS140311718  |k 0/910000/  |k 1/910000/910500/  |p 2 
999 |a KXP-PPN1698605188  |e 366876302X 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"22 February 2016"}],"id":{"doi":["10.1128/AAC.00157-16"],"eki":["1698605188"]},"name":{"displayForm":["Éanna Forde, André Schütte, Emer Reeves, Catherine Greene, Hilary Humphreys, Marcus Mall, Deirdre Fitzgerald-Hughes, Marc Devocelle"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"note":["Gesehen am 09.06.21"],"disp":"Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosisAntimicrobial agents and chemotherapy","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"306316919","corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society for Microbiology","role":"isb"}],"language":["eng"],"pubHistory":["1.1972 -"],"titleAlt":[{"title":"AAC"}],"part":{"extent":"9","volume":"60","text":"60(2016), 5, Seite 2813-2821","issue":"5","pages":"2813-2821","year":"2016"},"title":[{"title_sort":"Antimicrobial agents and chemotherapy","title":"Antimicrobial agents and chemotherapy","subtitle":"AAC"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["publ. by the American Society for Microbiology"]},"origin":[{"dateIssuedKey":"1972","publisher":"Soc.","dateIssuedDisp":"1972-","publisherPlace":"Washington, DC"}],"id":{"issn":["1098-6596"],"zdb":["1496156-8"],"eki":["306316919"]}}],"title":[{"title_sort":"Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis","title":"Differential in vitro and in vivo toxicities of antimicrobial peptide prodrugs for potential use in cystic fibrosis"}],"person":[{"given":"Éanna","family":"Forde","role":"aut","roleDisplay":"VerfasserIn","display":"Forde, Éanna"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schütte, André","given":"André","family":"Schütte"},{"given":"Emer","family":"Reeves","role":"aut","roleDisplay":"VerfasserIn","display":"Reeves, Emer"},{"family":"Greene","given":"Catherine","roleDisplay":"VerfasserIn","display":"Greene, Catherine","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Humphreys, Hilary","given":"Hilary","family":"Humphreys"},{"roleDisplay":"VerfasserIn","display":"Mall, Marcus A.","role":"aut","family":"Mall","given":"Marcus A."},{"roleDisplay":"VerfasserIn","display":"Fitzgerald-Hughes, Deirdre","role":"aut","family":"Fitzgerald-Hughes","given":"Deirdre"},{"given":"Marc","family":"Devocelle","role":"aut","display":"Devocelle, Marc","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 20.05.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1698605188","language":["eng"]} 
SRT |a FORDEEANNADIFFERENTI2220